Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Novartis is buying AveXis, a small biotech based in a north Chicago suburb, for $8.7 billion to strengthen gene therapy capabilities.
by Adam Feuerstein
Apr 09, 2018
1 minute
Novartis is acquiring AveXis for $8.7 billion to strengthen its gene therapy unit, adding a promising but still experimental treatment targeting a fatal childhood disease.
AveXis, a small biotech
You’re reading a preview, subscribe to read more.
Start your free 30 days